Alector (ALEC)
(Delayed Data from NSDQ)
$5.75 USD
+0.11 (1.95%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $5.74 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.75 USD
+0.11 (1.95%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $5.74 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 58.2% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alector (ALEC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 130.77% and 64.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -245.95% and 73.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector's (ALEC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Alector (ALEC) Stock Jumps 57.1%: Will It Continue to Soar?
by Zacks Equity Research
Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 2.94% and -35.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.